Title: Cancer is a Disease of Abnormal Growth Regulation
1Cancer is a Disease of Abnormal Growth Regulation
2Regulation of Cell Growth
- In normal tissue, cell numbers are precisely
controlled by balancing cell proliferation, with
differentiation and death (apoptosis). - All of these processes are affected in during
carcinogenesis.
3Regulation of Cell Growth
- Normal cell growth occurs in response to soluble
peptide growth factors. (mostly stimulatory). - Normal cell growth is inhibited by interaction
with neighboring cells (contact inhibition). - Normal cell growth requires contact with
substratum (anchorage-dependent).
4Cancer Cell Growth
- Tumor cells have reduced requirement for growth
factors. - Lack sensitivity to growth inhibitors
- Resistance to programmed cell death (apoptosis)
5Growth Factors
- Soluble peptides that interact with cells via
specific receptors located in the cell membrane. - Autocrine
- Paracrine
- Endocrine
6Growth Factors
TyK
TyK
7Growth Factor Receptors
TyK
TyK
8Tyrosine Phosphorylation
TyK
TyK
9Tyrosine phosphorylation recruits and activates
signaling proteins
TyK
TyK
10Phosphatidyl Inositol-3 Kinase
PI-3K
TyK
PI-3K
TyK
11Phosphatidyl Inositol-3 Kinase
PI-3K
TyK
PI-3K
TyK
12Recruitment of AKT and PDK1
PDK1
PI-3K
AKT/PKB
TyK
PI-3K
TyK
AKT/PKB
PDK1
13Activation of AKT and PDK1
PDK1
PI-3K
AKT/PKB
TyK
PI-3K
TyK
AKT/PKB
PDK1
14PDK1 Substrates
PDK1
PI-3K
AKT/PKB
TyK
PI-3K
TyK
PKC?
AKT/PKB
S6K
PKC?
PDK1
S6K
15AKT/PKB Substrates
PDK1
PI-3K
AKT/PKB
TyK
PI-3K
TyK
BAD Caspase 9
AKT/PKB
GSK3
PDK1
BAD Caspase 9
Cyclin D
16PTEN Inhibition of PI-3K
PTEN
PI-3K
TyK
PI-3K
TyK
PDK1
PTEN
AKT/PKB
17MAP kinase signaling
TyK
TyK
shc
shc
18Recruitment of GTPGDP Exchange Factor (GEF)
SOS
TyK
Grb2
TyK
shc
SOS
shc
Grb2
19Activation of RAS
RAS
GTP
SOS
GDP
TyK
Grb2
TyK
shc
SOS
shc
Grb2
20Inhibition of RAS
RAS
NF-1
GDP
SOS
TyK
Grb2
TyK
shc
SOS
shc
Grb2
21Activation of RAF
RAS
RAF
GTP
SOS
TyK
Grb2
TyK
shc
SOS
shc
Grb2
22RAF Substrates
RAS
RAF
GTP
SOS
MEK1, MEK2
TyK
Grb2
TyK
shc
SOS
shc
Grb2
ERK1/2
23Erk1/2 Substrates
RAS
RAF
GTP
SOS
Paxillin
TyK
RSK1-4, MSK1,2, MNK1,2
Grb2
TyK
shc
SOS
shc
Grb2
ERK1/2
c-jun c-fos
Bad GSK3 4EBP1 eIF4E et al
c-fos c-myc
24Activation of PLC?
TyK
PLC?
IP3 DAG
TyK
PLC?
PKC Ca
25Cell Adhesion molecules
Integrins
FAK
PI3K others
Actin Cytoskeleton
26Cell signaling and cancers
- Activating mutations in RTKs
- Activating mutations in RAS (reduced GTPase
activity) - Activating mutations in AKT or inactivating
mutations in PTEN - Mutations in more distal components are infrequent
27Cell Cycle Progression
- The cell cycle is the orderly progression of
events that occurs following growth stimulation
and results in the generation of 2 daughter
cells. - Cell cycle progression is regulated at specific
checkpoints. - Checkpoint control is abnormal in cancer cells.
28Growth signals cause cell cycle progression
RB
G1
S
CDK/Cyclins
G0
G2
M
29G0 to G1 progression requires specific signals
Involves activation of a large number of genes
but regulation is not well Worked out. Likely
to involve events mediated by cell-cell and
cell-substratum interactions.
G1
G0
30G1 to S progression
RB
G1
S
CDK4/D Cyclins
31G1 to S progression
RB
G1
S
CDK4/D Cyclins
Phosphorylation of RB results in its dissociation
from E2F transcriptional complexes. E2F
regulates transcription of cyclin E, DNA
polymerases, thymidine kinase, dihydrofolate
reductase and others
32G1 to S progression
RB
G1
S
CDK4/D Cyclins
Inhibitors of Cdk4 p16INK4 p21 p27
33Regulation of G1 to S progression is frequently
abnormal in cancers.
RB
G1
S
CDK4/D Cyclins
-Cdk4 inhibitors are frequently mutated in human
cancers. -Cyclin expression is increased in some
cancers -Cdk4 is activated in some cancers
34S to G2 progression
S
CDK2/Cyclins A E
G2
35G2 to M progression
CDK1/Cyclins A/B
G2
M
36Checkpoint control - G1/S
- p53 - Activated by DNA damage. Allows repair
prior to initiating new DNA synthesis - Guardian
of Genome - p53 - Effects mediated by p21
- p53 - Stabilized by p14Arf.
37Checkpoint control - G2/M
- ATM, RAD proteins - Activated by DS-DNA breaks.
- At G2/M, effects mediated by CDC25 phosphatase,
which causes disruption of CDK2/Cyclin B complex.
CHK kinases also required. BRCA1/2 may also
function in DS repair. - At G1/S, effects mediated by p53 (via p21).
38Checkpoint control
- Loss of checkpoint control is common in cancers.
- Loss of checkpoint control is a major cause of
genetic instability in cancer cells. - Inherited mutations in checkpoint proteins are
associated with increase risk of cancer.
39Programmed Cell Death
- Apoptosis
- Characteristic morphologic changes
- Cell shrinkage
- Cytoplasmic blebs
- Chromatin condensation
- Death mediated by specific proteases (caspases)
- Phagocytosis by macrophages
40Extrinsic Pathway
- Receptor-Mediated
- FAS
- TNFR1
- Interaction with ligand results in clustering of
caspase-8 and auto-cleavage - Active caspase-8 activates downstream caspases,
which ultimately leads to degradation of cellular
contents.
41Intrinsic Pathway
- Mediated by increased mitochondrial permeability
- release of Cytochrome c from mitochondria to
cytoplasm - Cyto C interacts with Apaf-1, which then cleaves
caspase-9 - Caspase-9 activates downstream caspases, which
ultimately leads to degradation of cellular
contents.
42Intrinsic Pathway
- Bcl family proteins mediate mitochondrial
permeability - Bcl-2 and Bcl-X inhibit permeability
- Bax, Bak, Bid and Bim promote permeability
- Mitochondrial permeability determined by the
balance of pro- and inhibitory Bcl family members
in mitochondrial membrane
43Regulation of Apoptosis
- Growth factors inhibit apoptosis
- AKT/PKB phosphorylates Bad and caspase-9,
inhibiting their function - Lack of growth factors results in death by
neglect - p53 promotes apoptosis in response to DNA damage
44p53 and Apoptosis
- p53 levels rapidly increase following exposure of
cells to a variety of cell stressors - DNA damage activates ATM, which phosphorylates
p53. - Phosphorylated p53 is a transcription factor
- p21
- Bax
45Apoptosis and Cancer
- p53 is mutated in over 50 of human cancers
- Decreased cell death in response to DNA damage
(i.e., many chemotherapeutic agents) - Increased mutability of DNA (lack of checkpoint
and lack of cell death) - Bcl-2 is overexpressed in a particular subtype of
lymphoma - Indolent disease characterized by accumulation of
cells (lack of cell death), rather than rapid
cell growth